These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 35427081)
41. Electrochemical immunosensor with graphene/gold nanoparticles platform and ferrocene derivatives label. Wang G; Gang X; Zhou X; Zhang G; Huang H; Zhang X; Wang L Talanta; 2013 Jan; 103():75-80. PubMed ID: 23200360 [TBL] [Abstract][Full Text] [Related]
42. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. Kalia LV Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800 [TBL] [Abstract][Full Text] [Related]
43. Enhanced diffusometric immunosensing with grafted gold nanoparticles for detection of diabetic retinopathy biomarker tumor necrosis factor-α. Chuang HS; Chen YJ; Cheng HP Biosens Bioelectron; 2018 Mar; 101():75-83. PubMed ID: 29040917 [TBL] [Abstract][Full Text] [Related]
44. Reduced cerebral blood flow in an Biju KC; Shen Q; Hernandez ET; Mader MJ; Clark RA J Cereb Blood Flow Metab; 2020 Dec; 40(12):2441-2453. PubMed ID: 31856640 [TBL] [Abstract][Full Text] [Related]
45. Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application. Xu L; Pu J Parkinsons Dis; 2016; 2016():1720621. PubMed ID: 27610264 [TBL] [Abstract][Full Text] [Related]
46. Plasma α-synuclein predicts cognitive decline in Parkinson's disease. Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072 [TBL] [Abstract][Full Text] [Related]
47. Combination of liquid crystal and deep learning reveals distinct signatures of Parkinson's disease-related wild-type α-synuclein and six pathogenic mutants. Yang X; Zhao X; Zhao H; Liu F; Zhang S; Zhang CX; Yang Z Chem Asian J; 2022 Jan; 17(2):e202101251. PubMed ID: 34877798 [TBL] [Abstract][Full Text] [Related]
48. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease. Chen CH; Lee BC; Lin CH J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681 [TBL] [Abstract][Full Text] [Related]
49. Semiautomated Support Photoelectrochemical Immunosensing Platform for Portable and High-Throughput Immunoassay Based on Au Nanocrystal Decorated Specific Crystal Facets BiVO Shu J; Qiu Z; Lin Z; Cai G; Yang H; Tang D Anal Chem; 2016 Dec; 88(24):12539-12546. PubMed ID: 28193072 [TBL] [Abstract][Full Text] [Related]
50. Development and evaluation of a gold nanourchin (GNU)-based sandwich architecture for SERS immunosensing in liquid. Tatar AS; Farcău C; Vulpoi A; Boca S; Astilean S Spectrochim Acta A Mol Biomol Spectrosc; 2022 May; 273():121069. PubMed ID: 35231760 [TBL] [Abstract][Full Text] [Related]
51. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease. Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018 [TBL] [Abstract][Full Text] [Related]
52. Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. Wang H; Atik A; Stewart T; Ginghina C; Aro P; Kerr KF; Seibyl J; Jennings D; ; Jensen PH; Marek K; Shi M; Zhang J Neurobiol Dis; 2018 Aug; 116():53-59. PubMed ID: 29705185 [TBL] [Abstract][Full Text] [Related]
53. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156 [TBL] [Abstract][Full Text] [Related]
54. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Zhou J; Broe M; Huang Y; Anderson JP; Gai WP; Milward EA; Porritt M; Howells D; Hughes AJ; Wang X; Halliday GM Acta Neuropathol; 2011 Jun; 121(6):695-704. PubMed ID: 21400129 [TBL] [Abstract][Full Text] [Related]
55. Quantitative Phosphoproteomic Analysis in Alpha-Synuclein Transgenic Mice Reveals the Involvement of Aberrant p25/Cdk5 Signaling in Early-stage Parkinson's Disease. He F; Qi G; Zhang Q; Cai H; Li T; Li M; Zhang Q; Chen J; Ming J; Tian B; Zhang P Cell Mol Neurobiol; 2020 Aug; 40(6):897-909. PubMed ID: 32016637 [TBL] [Abstract][Full Text] [Related]
56. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease. Pavlou MAS; Pinho R; Paiva I; Outeiro TF Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855 [TBL] [Abstract][Full Text] [Related]
57. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734 [TBL] [Abstract][Full Text] [Related]